Combretastatin is also reported to be able to inhibit angiogenesis, a process essential for tumor growth.

This increase was attributed to its ability to inhibit angiogenesis as it had in breast cancer models.

However, recent studies indicate that it actually inhibits angiogenesis.

One is at the N-terminus and is responsible for inhibiting angiogenesis.

Dz13 has been shown to inhibit tumour growth and angiogenesis.

Hence, it is under investigation for the treatment of glioblastoma by inhibiting angiogenesis.

However, exposure to a protein that inhibits Slit2 also inhibits angiogenesis.

TSP1 contains three type I repeats, only the second two of which have been found to inhibit angiogenesis.

The type I repeat motif is more effective than the entire protein at inhibiting angiogenesis and contains not one but two regions of activity.

The antiangiogenic residues 24-57 were shown to be sufficient at inhibiting angiogenesis.